The pace of innovation in oncology is extraordinary. New targets, treatment modalities and increasingly personalised approaches are creating possibilities that would have seemed out of reach only a few years ago. But greater choice does not necessarily make treatment decisions easier. As the treatment landscape becomes more complex, oncologists are increasingly facing questions that clinical data alone may not immediately answer. When should treatment change? Which therapy should come first? Who genuinely needs more treatment, and who could safely receive less? And, importantly, how do we ensure that scientific progress translates into meaningful improvements for patients? What If The Next Breakthrough Isn’t A New Treatment, But Knowing When To Change It? Precision oncology has traditionally focused on matching patients to therapies based on tumour characteristics identified at diagnosis. Increasingly, however, new technologies are creating opportunities to monitor how tumour biology changes during treatment and respond accordingly. SAFFRON demonstrated the potential of targeting MET-driven resistance following osimertinib in EGFR-mutated NSCLC, while KRASCENDO-1 reinforced the potential of next-generation inhibitors in KRAS G12C-mutated NSCLC. Emerging research into extrachromosomal DNA (ecDNA) adds another layer, suggesting that resistance may involve more complex mechanisms than acquired mutations alone and potentially opening opportunities to anticipate and disrupt tumour adaptation. This shifts the question from simply deciding which treatment to use towards understanding when treatment should change. Proactive monitoring could inform decisions about when to intensify, switch or combine therapies, but it also carries financial and emotional burden for patients. The challenge will be determining where this proactive intervention genuinely translates into better outcomes. When The Same Patient Population Could Benefit From Different ADCs, Which Should Come First? Antibody-drug conjugates (ADCs) continue to expand across tumour types and disease stages, with developments involving targets including HER2, TROP2, HER3, Nectin-4, CLDN18.2, B7-H4, B7-H3 and CDH6 As ADCs targeting different antigens are developed for the same patient populations, questions arise about which to use first and which to reserve for later lines This decision can be complex, as target expression does not always predict response, with payload characteristics, bystander effects and underlying tumour biology all influencing efficacy Safety and tolerability also become important as ADCs move into earlier lines, where cumulative toxicity is especially relevant More options undoubtedly create opportunities for patients, but they also create harder choices for clinicians. With limited evidence to guide sequencing, understanding what drives those choices and what evidence clinicians need to differentiate between options will become increasingly important. Is The Next Immunotherapy Breakthrough About Doing More or Doing Something Different? Immuno-oncology is also moving beyond PD-(L)1 inhibition, with personalised cancer vaccines, bispecific antibodies, T-cell engagers and increasingly sophisticated immune combinations creating new possibilities. INTerpath-001 showed the potential of individualised mRNA neoantigen therapy combined with pembrolizumab to improve recurrence-free survival in resected melanoma. This points towards a new paradigm; patient-specific immunotherapy designed to target unique tumour biology and potentially build long-term immune memory against recurrence. Bispecific antibodies and T-cell engagers also present new ways to overcome existing limitations, from simultaneously targeting immune suppression and angiogenesis through PD-1/VEGF inhibition to directly recruiting T cells against tumour-associated antigens. Yet contrasting results across perioperative immunotherapy trials, especially in bladder cancer, reinforce an important point: apparently similar approaches are not necessarily interchangeable. Differences in mechanism, treatment setting, tumour biology and patient selection can substantially influence outcomes. But we are yet to uncover which biological limitations of existing immunotherapies can genuinely be overcome by new immune mechanisms, how can clinicians identify the patients most likely to benefit from these approaches and most importantly how to ensure fair and wide access to personalised therapies. When Does More Treatment Stop Meaning Better Treatment? As cancer treatments become increasingly effective, there is growing interest in whether some patients could safely receive less treatment and whether a personalised intensification approach may be beneficial for others. Findings from perioperative regimens are placing greater scrutiny on the contribution of individual treatment components. VOLGA, for example, demonstrated the efficacy of neoadjuvant EV + durvalumab in MIBC, while the addition of tremelimumab was considered too toxic. At the same time, advances in ctDNA could provide new ways to guide treatment intensification and de-escalation. In bladder cancer, emerging ctDNA findings raise questions around adjuvant treatment selection and whether molecular response could help identify candidates for bladder preservation. But identifying patients who are likely to do well is not the same as proving that they can safely receive less treatment. As our ability to identify risk improves, clinicians will need increasing confidence in deciding who genuinely benefits from treatment intensification and who could receive less without compromising long-term outcomes. How Can We Close The Access Gap? Alongside these clinical questions sits an equally important challenge: ensuring innovation actually reaches the patients who could benefit. ESMO 2026 continued to highlight the gap between the pace of scientific progress and the ability of health systems to deliver it. Across Europe, only 51% of newly EMA-approved medicines are available on average. And while individualised therapies such as mRNA neoantigen treatment signal a new era of patient-specific cancer care, this exposes a critical challenge: the more personalised and complex innovation becomes, the greater the risk of healthcare disparities. Differences in standards of care can also affect clinical trial design. When advanced standards of care are already established in some countries but remain unavailable in others, generating evidence that is relevant across markets becomes increasingly difficult, potentially creating further barriers to approval and access. Evidence generation therefore needs to evolve alongside treatment innovation. Reliable early predictors of long-term benefit could help shorten development and approval timelines without always having to wait for overall survival data to mature. Ultimately, increasingly personalised oncology cannot come at the cost of increasingly unequal access. Is Oncology Innovation Moving Faster Than Our Ability To Make Sense Of It? Across all of these developments, there is a common thread. The challenge is no longer simply a lack of treatment options. Increasingly, it is deciding between a growing number of possibilities when the “right” path may be less obvious. Which ADC comes first? When should a therapy change? When is intensification justified? When can treatment safely be reduced? Which patients are most likely to benefit from proactive monitoring and intervention? How to safely identify candidates for bladder preservation? These Are Scientific and Clinical Questions, But They Are Also Human Decision-Making Questions. As treatment pathways become more complex, clinicians and patients are being asked to interpret growing volumes of evidence, weigh competing benefits and risks, navigate uncertainty and make decisions where there may be no obvious right answer. Understanding the behaviours, beliefs and heuristics behind these choices could therefore become just as important as understanding the clinical landscape itself. At HRW, we are fascinated by what drives people to make the decisions they do. By combining deep oncology expertise with behavioural science, we explore not only what oncologists and patients choose, but why, helping healthcare teams understand how new evidence, treatment options and changing pathways are likely to translate into real-world behaviour. If the oncology landscape you work in is becoming harder to navigate, and you want to better understand what is driving the decisions being made within it, we’d love to explore those questions with you. Fill in the Contact Form below or reach out at HRW-ORBIT@hrwhealthcare.com By Marianne Ibrahim and Asha Varma Apply Now!